Sotalol

Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3].

Product Specifications

CAS Number

[3930-20-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Adrenergic Receptor; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sotalol.html

Solubility

10 mM in DMSO

Smiles

CS(=O)(NC1=CC=C(C(O)CNC(C)C)C=C1)=O

Molecular Formula

C12H20N2O3S

Molecular Weight

272.36

Precautions

P261-P280-P302+P352

References & Citations

[1]Marta Reyes-Corral, et al. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019 Apr;369 (1) :152-162.|[2]Xiaomei Li, et al. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. Pediatr Cardiol. 2017 Oct;38 (7) :1450-1455.|[3]Kinga K Borowicz-Reutt, et al. Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.Pharmacol Rep. 2021 Apr;73 (2) :516-524.